Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 in GRPR+ Tumors
NCT07661641Phase 1Recruiting
- Sponsor
- Alpha-9 Oncology
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 in breast cancer, prostate cancer (PCa), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Alpha-9 Oncology. Primary endpoints: Incidence of Adverse Events by Frequency, Duration, and Severity, Number of Patients with Dose-Limiting Toxicities at 28 days and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
[177Lu]Lu-A9-0631[225Ac]Ac-A9-0642
03
Conditions
breast cancerprostate cancer (PCa)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT07661641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661641.